Bristol-Myers Squibb Company

A→Z catalog of Bristol-Myers Squibb

A

• Abilify (regional, co-rights) — Aripiprazole — Schizophrenia, bipolar, MDD adjunct — 10–30 mg QD.

• Abraxane — Paclitaxel protein-bound nanoparticles — Breast, lung, pancreatic cancer — 260 mg/m² IV q3w (per regimen).

• Abecma — Idecabtagene vicleucel — BCMA CAR-T, relapsed/refractory multiple myeloma — Single IV infusion per kg cell dose.

• Atripla (co-developed with Gilead, legacy HIV) — Efavirenz + tenofovir DF + emtricitabine — HIV — 1 tab QD.

• Azactam — Aztreonam — Gram-negative bacterial infections — 1–2 g IV/IM q8–12h.

B

• Baraclude — Entecavir — Chronic HBV infection — 0.5–1 mg QD.

• Breyanzi — Lisocabtagene maraleucel — CD19 CAR-T for LBCL, FL, CLL — Single IV infusion (dose by kg).

• Brystol legacy antihypertensives (Capoten, etc.).

C

• Capoten — Captopril — Hypertension, HF, diabetic nephropathy — 25–50 mg TID.

• Caelyx / Doxil — Pegylated liposomal doxorubicin — Ovarian cancer, myeloma, Kaposi’s sarcoma — 30–50 mg/m² IV q4w.

• Clopidogrel (Plavix) — see P.

• Cymbalta (regional rights) — Duloxetine — Depression, anxiety, neuropathy — 30–60 mg QD.

D

• Daklinza — Daclatasvir — HCV in combo therapy — 60 mg QD.

• Delipec (regional legacy).

• Doxil / Caelyx — see C.

E

• Empliciti — Elotuzumab — Relapsed multiple myeloma — IV infusion with len/dex per cycle.

• Eliquis — Apixaban — NVAF, VTE treatment/prevention — 5 mg BID (2.5 mg BID in select).

• Etopophos — Etoposide phosphate — Small-cell lung, testicular cancer — IV per cycle.

F

• Fampyra (regional) — Fampridine — MS walking disability — 10 mg BID.

• Fluorouracil (Adrucil) — 5-FU — Various solid tumors — IV infusion/bolus per protocol.

G

• Glucophage (co-rights) — Metformin — T2DM — 500–2000 mg/day.

• Glucovance — Metformin + glyburide.

H

• Hydrea — Hydroxyurea — Sickle cell disease, CML, polycythemia vera — 500 mg–2 g daily individualized.

I

• Inrebic — Fedratinib — Myelofibrosis — 400 mg QD.

• Ixempra — Ixabepilone — Metastatic breast cancer — 40 mg/m² IV q3w.

• Intron A — Interferon alfa-2b — Chronic HBV/HCV, melanoma, hairy cell leukemia — Per regimen.

J

• Juxtapid (regional rights) — Lomitapide — HoFH — 5–60 mg QD.

K

• Kombiglyze XR (co-rights with AZ) — Saxagliptin + metformin XR — T2D.

• Komboglyze — same.

L

• Lynparza (co-developed, AZ main rights) — Olaparib — Ovarian, breast, prostate, pancreatic cancers.

• Lotemax distribution in legacy dermatology.

M

• Megace ES — Megestrol acetate — Anorexia/cachexia, endometrial carcinoma — 40–320 mg/day.

• Mepron — Atovaquone — PCP prevention/treatment — 750 mg BID with food.

• Mylotarg — Gemtuzumab ozogamicin — CD33+ AML — IV infusion per protocol.

• Mitoxantrone — Mitoxantrone HCl — Secondary progressive MS, AML, prostate cancer (hormone-refractory) — IV q3m (MS), other regimens oncology.

N

• Navoban — Tropisetron — CINV prophylaxis — 5 mg IV/PO daily × 6 days.

• Nulojix — Belatacept — Kidney transplant immunosuppression — IV at Weeks 0,2,4,8,12,16 then q4w.

O

• Opdivo — Nivolumab — Multiple cancers (melanoma, NSCLC, RCC, HCC, esophageal, Hodgkin’s, etc.) — IV q2–4w (240 mg q2w or 480 mg q4w).

• Orencia — Abatacept — RA, JIA, PsA — IV 10 mg/kg q4w or 125 mg SC weekly.

• Onureg — Oral azacitidine — AML maintenance — 300 mg QD Days 1–14 each 28-day cycle.

P

• Pomalyst / Imnovid — Pomalidomide — Multiple myeloma — 4 mg QD Days 1–21 of 28.

• Plavix — Clopidogrel — Antiplatelet, ACS, stenting — 75 mg QD (with/without 300 mg load).

• Paraplatin — Carboplatin — Ovarian cancer, lung, others — IV dose = AUC × GFR +25.

Q

• Questran — Cholestyramine resin — Hyperlipidemia, pruritus cholestasis, diarrhea — 4 g powder 1–6× daily.

R

• Revlimid (Celgene acquisition) — Lenalidomide — Multiple myeloma, MDS, lymphoma — 10–25 mg/day cycle-based.

• Reblozyl (with Acceleron) — Luspatercept — Beta-thalassemia anemia, MDS anemia — 1 mg/kg SC q3w.

• Rubraca (co-promote legacy) — Rucaparib.

S

• Sprycel — Dasatinib — CML, Ph+ ALL — 100 mg QD.

• Sustiva (legacy HIV with Gilead) — Efavirenz.

• Syprine — Trientine — Wilson’s disease — 750–1500 mg/day in divided doses.

T

• Thalomid — Thalidomide — Multiple myeloma, erythema nodosum leprosum — 100–200 mg QD.

• Tegretol (legacy rights regional) — Carbamazepine.

• Taxol (legacy, now generic) — Paclitaxel.

U

• Ubrelvy (partner rights regional) — Ubrogepant — Migraine acute — 50–100 mg PO PRN.

V

• Vidaza — Azacitidine — AML, MDS — 75 mg/m² SC/IV ×7 days q28d.

• *Venclexta (AbbVie/BMS co-dev) — Venetoclax — CLL, AML.

• Vyxeos — Liposomal daunorubicin + cytarabine — Secondary AML — 44/100 mg/m² IV Days 1,3,5.

Y

• Yervoy — Ipilimumab — Melanoma, RCC, NSCLC combo with nivolumab — 3 mg/kg IV q3w ×4 (± Opdivo).

Z

• Zerit — Stavudine — HIV (legacy, limited use) — 40 mg BID.

• Zeposia — Ozanimod — MS, ulcerative colitis — 0.92 mg QD after titration.